Advanced Search
CHENG Ying. Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 745-750. DOI: 10.3971/j.issn.1000-8578.2021.21.0472
Citation: CHENG Ying. Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 745-750. DOI: 10.3971/j.issn.1000-8578.2021.21.0472
shu

Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer

  • Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun 130012, China

Funding: 

Science and Technology Agency of Jilin Provincial Project 202002063JC

More Information
  • Received Date: April 24, 2021
  • Revised Date: June 16, 2021
  • Available Online: January 12, 2024
    Graphical Abstract
    • Abstract

  • In recent years, immunotherapy has made revolutionary breakthroughs in the field of lung cancer and has become an indispensable treatment for patients with advanced NSCLC. More patients treated with immunotherapy have achieved long-term survival. At present, immunotherapy is still a hot research hotspot. In order to better understand the development and changes of immunotherapy for advanced NSCLC, this article systematically and comprehensively reviews the clinical research progress of immunotherapy.

    • FullText(HTML)

  • Competing interests:The authors declare that they have no competing interests.

    • References (55)
  • [1]
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
    [2]
    Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. doi: 10.1056/NEJMoa1606774
    [3]
    Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs. platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%[J]. Ann Oncol, 2020, 31(suppl_4): S1181-S1182. http://www.sciencedirect.com/science/article/pii/S092375342042366X
    [4]
    Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830. doi: 10.1016/S0140-6736(18)32409-7
    [5]
    Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC[J]. N Engl J Med, 2020, 383(14): 1328-1339. doi: 10.1056/NEJMoa1917346
    [6]
    Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial[J]. Lancet, 2021, 397(10274): 592-604. doi: 10.1016/S0140-6736(21)00228-2
    [7]
    Seto T, Nosaki K, Shimokawa M, et al. WJOG @Be study: A phase Ⅱ study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expression[J]. Ann Oncol, 2020, 31(suppl_4): S1185-S1186. http://www.sciencedirect.com/science/article/pii/S0923753420423701
    [8]
    Boyer M, Mclean J, Xu L, et al. Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598[J]. J Thorac Oncol, 2018, 13(10): S462. http://www.sciencedirect.com/science/article/pii/S1556086418315235
    [9]
    Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: The right path to achieve cancer cure?[J]. Ann Oncol, 2015, 26(9): 1813-1823. doi: 10.1093/annonc/mdv209
    [10]
    Qiao M, Jiang T, Ren S, et al. Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer: Where do we stand?[J]. Clin Lung Cancer, 2018, 19(1): 1-11. doi: 10.1016/j.cllc.2017.06.005
    [11]
    Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508. doi: 10.1016/S1470-2045(16)30498-3
    [12]
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092. doi: 10.1056/NEJMoa1801005
    [13]
    Gray J, Rodríguez-Abreu, Powell SF, et al. Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189[J]. J Thorac Oncol, 2021, 16(3): S224. http://www.sciencedirect.com/science/article/pii/S1556086421001830
    [14]
    Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051. doi: 10.1056/NEJMoa1810865
    [15]
    Robinson AG, Vicente D, Tafreshi A, et al. First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407[J]. J Thorac Oncol, 2021, 16(4): S748-S749. http://www.sciencedirect.com/science/article/pii/S1556086421019390
    [16]
    Cheng Y, Zhang L, Hu J, et al. Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC[J]. Ann Oncol, 2019, 30(suppl_9): ix201-ix202. http://www.researchgate.net/publication/337475979_LBA20Keynote-407_China_Extension_study_Pembrolizumab_pembro_plus_chemotherapy_in_Chinese_patients_with_metastatic_squamous_NSCLC
    [17]
    Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3): 305-314. doi: 10.1016/S2213-2600(20)30365-9
    [18]
    Yang Y, Wang Z, Fang J, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)[J]. J Thorac Oncol, 2020, 15(10): 1636-1646. doi: 10.1016/j.jtho.2020.07.014
    [19]
    Lu S, Wang J, Yu Y, et al. Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial[J]. J Thorac Oncol, 2021, S1556-0864(21)02176-6. http://www.ncbi.nlm.nih.gov/pubmed/34033975
    [20]
    Zhou C, Wu L, Fan Y, et al. ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)[J]. Ann Oncol, 2020, 31(suppl_9): S1186. http://www.sciencedirect.com/science/article/pii/S0923753420423713
    [21]
    Wang J, Lu S, Yu X, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2021, 7(5): 709-717. doi: 10.1001/jamaoncol.2021.0366
    [22]
    Zhou C, Ren S, Chen J, et al. Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase Ⅲ trial[J]. J Thorac Oncol, 2021, 16(suppl_4): S748.
    [23]
    Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5): 325-340. doi: 10.1038/nrclinonc.2018.29
    [24]
    Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301. doi: 10.1056/NEJMoa1716948
    [25]
    Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. doi: 10.1016/S2213-2600(19)30084-0
    [26]
    Jotte RM, Batus M, Bernicker E, et al. IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease[J]. J Clin Oncol, 2020, 38(suppl_15): e21637. http://www.researchgate.net/publication/341633517_IMpower150_Exploratory_efficacy_analysis_in_patients_pts_with_bulky_disease
    [27]
    West H, Cappuzzo F, Reck M, et al. IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations[J]. Ann Oncol, 2020, 31(suppl_4): S817-S818. http://www.sciencedirect.com/science/article/pii/S0923753420415753
    [28]
    Lee JS, Sugawara S, Kang JH, et al. Randomized phase Ⅲ trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC[J]. Ann Oncol, 2020, 31(suppl_4): S1184-S1185. http://www.sciencedirect.com/science/article/pii/S0923753420423695
    [29]
    Nishio M, Peled N, Zer A, et al. Phase Ⅲ LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC[J]. Ann Oncol, 2020, 31(suppl_4): S848-S849. http://www.sciencedirect.com/science/article/pii/s0923753420416230
    [30]
    Chu T, Zhong R, Zhong H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC[J]. J Thorac Oncol, 2021, 16(4): 643-652. doi: 10.1016/j.jtho.2020.11.026
    [31]
    Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J]. Proc Natl Acad Sci U S A, 2010, 107(9): 4275-4280. doi: 10.1073/pnas.0915174107
    [32]
    Hellmann MD, Paz-Ares L, Caro RB, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019, 381(21): 2020-2031. doi: 10.1056/NEJMoa1910231
    [33]
    Cho BC, Reinmuth N, Lee KH, et al. Efficacy and safety of first-line durvalumab (D) +/- tremelimumab (T) vs. platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC[J]. Ann Oncol, 2019, 30(suppl_2): ii79-ii80. http://www.sciencedirect.com/science/article/pii/S0923753419302613
    [34]
    Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 198-211. doi: 10.1016/S1470-2045(20)30641-0
    [35]
    Rodriguez-Abreu D, Johnson ML, Hussein M, et al. Primary analysis of a randomized, double-blind, phase Ⅱ study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)[J]. J Clin Oncol, 2020, 38(suppl_15): 9503. http://www.researchgate.net/publication/346799017_253_Anti-TIGIT_antibodies_require_enhanced_FcgR_co-engagement_for_optimal_T_and_NK_cell-dependent_anti-tumor_immunity
    [36]
    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(2): 123-135. doi: 10.1056/NEJMoa1504627
    [37]
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. doi: 10.1056/NEJMoa1507643
    [38]
    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550. doi: 10.1016/S0140-6736(15)01281-7
    [39]
    Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265. doi: 10.1016/S0140-6736(16)32517-X
    [40]
    Gettinger S, Horn L, Jackman D, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study[J]. J Clin Oncol, 2018, 36(17): 1675-1684. doi: 10.1200/JCO.2017.77.0412
    [41]
    Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001[J]. Ann Oncol, 2019, 30(4): 582-588. doi: 10.1093/annonc/mdz011
    [42]
    Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase Ⅲ Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2021, 39(7): 723-733. doi: 10.1200/JCO.20.01605
    [43]
    Wu YL, Lu S, Cheng Y, et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase Ⅲ Clinical Trial[J]. J Thorac Oncol, 2019, 14(5): 867-875. doi: 10.1016/j.jtho.2019.01.006
    [44]
    Shi Y, Wu L, Yu X, et al. RETRACTED: ORIENT-3: A randomized, open-label, phase Ⅲ study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)[J]. Ann Oncol, 2020, 31(suppl_7): S1428. http://www.sciencedirect.com/science/article/pii/S0923753421000181
    [45]
    Gao G, Wang Y, Ren S, et al. Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC[J]. Ann Oncol, 2020, 31(suppl_4): S819. http://www.sciencedirect.com/science/article/pii/S0923753420415777
    [46]
    Arrieta O, Barron F, Carmona CA, et al. Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients[J]. J Thorac Oncol, 2019, 14(10): S291. http://www.researchgate.net/publication/336696448_MA1103_Pembrolizumab_Plus_Docetaxel_Increases_Progression-Free_Survival_Compared_with_Docetaxel_Alone_in_Previously_Treated_Advanced_Non-Small_Cell_Lung_Cancer_Patients
    [47]
    Zhou C, Xiong A, Li W, et al. A Phase Ⅱ Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)[J]. J Thorac Oncol, 2021, 16(3): S636. http://www.researchgate.net/publication/350199926_P7703_A_Phase_II_Study_of_KN046_Bispecific_Anti-PD-L1CTLA-4_in_Patients_pts_with_Metastatic_Non-Small_Cell_Lung_Cancer_NSCLC
    [48]
    Paz-Ares LG, Kim TM, Baz DV, et al. Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1[J]. J Clin Oncol, 2018, 36(suppl_15): 9017. http://www.researchgate.net/publication/327452356_Results_from_a_second-line_2L_NSCLC_cohort_treated_with_M7824_MSB0011359C_a_bifunctional_fusion_protein_targeting_TGF-b_and_PD-L1
    [49]
    Giaccone G, Felip E, Cobo M, et al. Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase Ⅲ ATALANTE-1 randomised trial[J]. Ann Oncol, 2020, 31(suppl_4): S814-S815. http://www.sciencedirect.com/science/article/pii/S0923753420415704
    [50]
    Ji M, Liu Y, Li Q, et al. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations[J]. Cancer Biol Ther, 2016, 17(4): 407-413. doi: 10.1080/15384047.2016.1156256
    [51]
    Dong ZY, Zhang JT, Liu SY, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer[J]. Oncoimmunology, 2017, 6(11): e1356145. doi: 10.1080/2162402X.2017.1356145
    [52]
    Gainor JF, Shaw AT, Sequist LV, et al. EGFR Mutations and ALK Rearr-angements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis[J]. Clin Cancer Res, 2016, 22(18): 4585-4593. doi: 10.1158/1078-0432.CCR-15-3101
    [53]
    Lee CK, Man J, Lord S, et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis[J]. J Thorac Oncol, 2017, 12(2): 403-407. doi: 10.1016/j.jtho.2016.10.007
    [54]
    Garassino MC, Cho BC, Kim JH, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(4): 521-536. doi: 10.1016/S1470-2045(18)30144-X
    [55]
    Zhang J, Zhou C, Zhao Y, et al. A PⅡ Study of Toripalimab, a PD-1 mAb in Combination with Chemotherapy in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies[J]. J Thorac Oncol, 2019, 14(10): S292. http://www.sciencedirect.com/science/article/pii/S1556086419312705
    • Related Articles

  • Related Articles

    [1]DUAN Xiaoyang, SHI Jian. Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 103-109. DOI: 10.3971/j.issn.1000-8578.2025.24.0856
    [2]WANG Jingyi, ZHONG Yuling, WU Lin. Immunotherapy for Advanced Non-small Cell Lung Cancer: Research Progress and Perspectives[J]. Cancer Research on Prevention and Treatment, 2024, 51(6): 409-418. DOI: 10.3971/j.issn.1000-8578.2024.24.0090
    [3]SUN Jiaqi, WANG Yudong. Treatment Strategy and Research Progress of Immune Microenvironment for Liver Metastasis of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 203-209. DOI: 10.3971/j.issn.1000-8578.2024.23.0878
    [4]ZHENG Jianhong, TIAN Lin, ZHAO Peiyan, LI Hui, CHENG Ying. Research Progress on Efficacy-related Biomarkers of Immunotherapy in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 127-133. DOI: 10.3971/j.issn.1000-8578.2024.23.0856
    [5]WANG Ganggang, WANG Xianhuo, ZHANG Huilai. Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1165-1173. DOI: 10.3971/j.issn.1000-8578.2023.23.0901
    [6]HAN Jing, CHEN Yarui, WANG Song, GUAN Quanlin. Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1139-1144. DOI: 10.3971/j.issn.1000-8578.2023.23.0447
    [7]WANG Tianming, ZHANG Liang, CHENG Ying. Progress of Research on Immune-related Pneumonia in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(8): 808-812. DOI: 10.3971/j.issn.1000-8578.2023.23.0075
    [8]SUN Yichu, LIANG Fei, XIA Youyou. Progress of Research on Radiotherapy Combined with Immunotherapy for Brain Metastases from Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 705-709. DOI: 10.3971/j.issn.1000-8578.2023.22.1322
    [9]MA Shishi, DAI Yuran, CHEN Xiaopin. Research Progress on Postoperative Adjuvant Therapy for Completely Resected Stage ⅠB Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 303-308. DOI: 10.3971/j.issn.1000-8578.2023.22.0933
    [10]JIANG Meilin, PENG Wenying, LI Jia, CHEN Bolin, WU Lin. Research Progress of Biomarkers for Immunotherapy on Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 805-810. DOI: 10.3971/j.issn.1000-8578.2018.17.1514

  • Cited by

    Periodical cited type(9)

    1. 张丽，王蕊. 动机行为转化渐进性护理模式对肺癌化疗患者的影响. 国际护理学杂志. 2024(02): 219-223 .
    2. 张蕾，钱震东，吴征斌，王静静. 衍生NLR作为进展期非小细胞肺癌免疫治疗反应预测性生物标志物的价值研究. 国际检验医学杂志. 2024(12): 1474-1481 .
    3. 杨淑燕，庄金满，刘宇航，朱金秀，林梦心，何斐. 基于CiteSpace的肺癌免疫治疗研究的可视化分析. 肿瘤防治研究. 2023(01): 43-51 . 本站查看
    4. 龙果，刘单，邓述恺. MLN4924通过抑制类泛素化通路上调人肺腺癌A549细胞中PD-L1的表达. 现代肿瘤医学. 2023(12): 2223-2228 .
    5. 张晓娟，岳冬丽，杨双宁，郝娜，王丽萍，董文杰. 卡瑞利珠单抗联合安罗替尼三线治疗晚期非小细胞肺癌的疗效观察. 肿瘤防治研究. 2023(06): 593-597 . 本站查看
    6. 李国强，席孝忠，陈洋. 吉西他滨和顺铂新辅助化疗联合手术治疗非小细胞肺癌的临床观察. 实用癌症杂志. 2023(09): 1533-1535+1539 .
    7. 丁艳. 卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌的临床效果及安全性. 名医. 2023(11): 159-161 .
    8. 陈瑜婷，黄玲，夏俊杰，邱宇，弋可，王金诚. 多原发肺癌的诊疗进展. 四川医学. 2022(07): 722-726 .
    9. 顾彤，姜瑜珩，丁姝，陈炜，罗超，于伟勇，陈小飞. CENPF通过上调ACKR3/CXCR7促进非小细胞肺癌EMT的研究. 肿瘤防治研究. 2022(12): 1245-1251 . 本站查看

    Other cited types(10)

Catalog

    Get Citation
    PDF
    XML
    Article views (2662) PDF downloads (1242) Cited by(19)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：18989924 Visits today：17472

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return